HiFiBiO Therapeutics Revenue and Competitors

Paris, France

Location

$179.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • HiFiBiO Therapeutics's estimated annual revenue is currently $14.3M per year.(i)
  • HiFiBiO Therapeutics's estimated revenue per employee is $155,000
  • HiFiBiO Therapeutics's total funding is $179.5M.

Employee Data

  • HiFiBiO Therapeutics has 92 Employees.(i)
  • HiFiBiO Therapeutics grew their employee count by 0% last year.

HiFiBiO Therapeutics's People

NameTitleEmail/Phone
1
VP, Head Research, France & Global CMCReveal Email/Phone
2
Senior Director, Head US Drug Intelligent Science and External InnovationReveal Email/Phone
3
Sr. Director, Head DIS France & EU Ext. InnovationReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M81-5%N/AN/A
#2
$19.5M126-2%N/AN/A
#3
$36.3M23422%N/AN/A
#4
$19.7M127-17%N/AN/A
#5
$14.3M920%$179.5MN/A
#6
$49.4M208-8%€201.1MN/A
#7
$44.5M287-3%N/AN/A
#8
$7.6M49N/AN/AN/A
#9
$6.4M41N/AN/AN/A
#10
$17.2M111-15%N/AN/A
Add Company

What Is HiFiBiO Therapeutics?

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com. HiFiBiO Therapeutics has operations in Paris, France, Cambridge, MA, USA and Hangzhou, China.

keywords:N/A

$179.5M

Total Funding

92

Number of Employees

$14.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HiFiBiO Therapeutics News

2022-04-06 - Epigenetic treatments: New allies for chemotherapies?

... how to apply this concept to humans from a therapeutic perspective. ... (CNRS/ESPCI Paris - PSL) and from company HiFiBio Therapeutics.

2021-06-15 - HiFiBiO Therapeutics secures $75M

HiFiBiO Therapeutics has raised $75 million in a Series D led by Mirae Asset Financial Group. Founded in 2013, the company is a developer of single-cell profiling technologies designed to accelerate biotherapeutics that combat cancer and autoimmune disorders. Select Additional Investors B Capi ...

2021-06-15 - China’s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group

HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion in asset ...

2021-06-15 - China’s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group

Premium HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.8M927%N/A
#2
$12.9M923%N/A
#3
$12.9M922%$23.1M
#4
N/A9216%N/A
#5
N/A9226%N/A